In addition, expression of GAS5 RNA in Pca tissue was inversely correlated with clinical features including PSA level, Gleason grade, and pathological stage, suggesting that GAS5 loss may serve as a biomarker for Pca progression and GAS5-ATK/mTOR pathway is a potential therapeutic target for the treatment of Pca [107]. The gene discussed is MTOR; the disease is posterior cortical atrophy.